雜志介紹

Breast Cancer Research雜志介紹

《Breast Cancer Research》是一本以English為主的開放獲取國際優(yōu)秀期刊，中文名稱乳腺癌研究，本刊主要出版、報道醫(yī)學-ONCOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進展，探討行業(yè)發(fā)展的思路和方法，以促進學術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為6.1，最新CiteScore 指數(shù)為12。

本刊近期中國學者發(fā)表的論文主要有：

• Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling

  Author: Liu, Heshu; Yan, Rui; Xiao, Zeru; Huang, Xuying; Yao, Jiannan; Liu, Jian; An, Guangyu; Ge, Yang

• MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer

  Author: Cao, Zhiwen; Liu, Rui; Li, Yang; Luo, Xinyi; Hua, Zhenglai; Wang, Xiangpeng; Xue, Zeyu; Zhang, Zhengjia; Lu, Cheng; Lu, Aiping; Liu, Yuanyan

• Association between human blood metabolome and the risk of breast cancer

  Author: Wang, Yu; Liu, Fanghua; Sun, Lulu; Jia, Yiming; Yang, Pinni; Guo, Daoxia; Shi, Mengyao; Wang, Aili; Chen, Guo-Chong; Zhang, Yonghong; Zhu, Zhengbao

• METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer

  Author: Ouyang, Dengjie; Hong, Tao; Fu, Mengdie; Li, Yitong; Zeng, Liyun; Chen, Qitong; He, Hongye; Wen, Ying; Cheng, Yan; Zhou, Meirong; Zou, Qiongyan; Yi, Wenjun

英文介紹

Breast Cancer Research雜志英文介紹

Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.